NEW YORK, June 20, 2017 /PRNewswire/ -- Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on BRCA1 and BRCA2 mutation in Cancer in 18 Major MarketsIt has long been established that BRCA1 and BRCA2 (BReast CAncer susceptibility gene) germline mutations confer a higher risk of developing ovarian or breast cancer in women that carry the mutation. However, it has also been established that BRCA1 and BRCA2 mutations also confer higher risk of developing cancers such as prostate, pancreatic, stomach and colorectal in individuals that carry the mutations.Read the full report: http://www.reportlinker.com/p04945249/Epiomic-Epidemiology-Series-BRCA-1-2-Mutation-in-Cancer-Forecast-in-18-Major-Markets.htmlThis report provides the current prevalent population for BRCA1 & BRCA2 mutations in cancer populations across 18 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Russia, Turkey, Saudi Arabia, Japan, China, Argentina, Brazil, Mexico, India, South Africa and Australia) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity. Providing a value-added level of insight from the analysis team at Black Swan, several of the main cancers with BRCA1 and BRCA2 mutation have been quantified and presented alongside the overall prevalence figures. BRCA1/2 mutations are most often associated with the following cancers:• Breast• Ovarian• Pancreatic• Prostate• StomachAnd less frequently with the following cancers:• CRC• Malignant melanoma • Kidney cancerThis report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report. Reason to buy• Able to quantify patient populations in global BRCA1 and BRCA2 mutations market to target the development of future products, pricing strategies and launch plans. • Gain further insight into the prevalence of the BRCA1 and BRCA2 mutations by cancer type and identify patient segments with high potential.• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.• Provide a level of understanding on the impact of the mutation on the prevalent population for specific cancer types.• Gain an understanding of the specific markets that have the largest number of BRCA1 and BRCA2 mutation patients.Read the full report: http://www.reportlinker.com/p04945249/Epiomic-Epidemiology-Series-BRCA-1-2-Mutation-in-Cancer-Forecast-in-18-Major-Markets.htmlAbout Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. http://www.reportlinker.com
__________________________Contact Clare: [email protected]
US: (339)-368-6001Intl: +1 339-368-6001
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/epiomic-epidemiology-series-brca-1--2-mutation-in-cancer-forecast-in-18-major-markets-2017-2027-300477003.html
SOURCE Reportlinker
